title: Immunological recovery and tumour-specific immunotherapeutic approaches to post-autologous haematopoietic stem cell transplantation.
abstract: Haematological recovery following autologous peripheral blood stem cell treatment is very rapid. Immune recovery is a more prolonged process requiring a year or more for full reconstitution. Because high-dose chemotherapy followed by autologous peripheral blood stem cell treatment results in (or is presumed to result in) minimal burden of residual malignant disease it provides a potentially ideal setting for immune-mediated anti-tumour therapy. The slow immune reconstitution following transplantation may however hamper the development of effective immunotherapy. Among different approaches proposed, we focus on the potential use of tumour antigens in conjunction with cellular therapy in an attempt to eliminate residual tumour following autologous transplantation.
authors.affiliation: University Hospital St Luc and Laboratory of Experimental Oncology and Haematology, Université Catholique de Louvain, Brussels, Belgium.
authors.forename: T
authors.initials: T
authors.lastname: Guillaume
authors.forename: D B
authors.initials: DB
authors.lastname: Rubinstein
authors.forename: M
authors.initials: M
authors.lastname: Symann
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000592:standards / Q000627:therapeutic use*; D006085:Graft Survival / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000592:standards; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000592:standards; D016219:Immunotherapy, Adoptive; D014182:Transplantation, Autologous / Q000379:methods / Q000592:standards
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines